GeneDx (NASDAQ:WGS) Posts Earnings Results, Beats Expectations By $0.66 EPS

GeneDx (NASDAQ:WGS) announced its quarterly earnings results on Tuesday. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66, Zacks reports. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. GeneDx updated its FY 2025 guidance to EPS.

GeneDx Trading Down 2.1 %

Shares of NASDAQ:WGS opened at $76.35 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The stock’s 50-day moving average is $76.48 and its 200-day moving average is $61.21. The company has a market cap of $2.10 billion, a P/E ratio of -24.55 and a beta of 2.01. GeneDx has a 52-week low of $4.34 and a 52-week high of $98.87.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 12,019 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44. Following the transaction, the chief financial officer now owns 32,932 shares of the company’s stock, valued at approximately $2,429,064.32. The trade was a 26.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total transaction of $130,041.36. Following the transaction, the chief executive officer now owns 3,937 shares of the company’s stock, valued at approximately $308,975.76. The trade was a 29.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 139,603 shares of company stock valued at $12,223,041. Insiders own 27.30% of the company’s stock.

Analyst Upgrades and Downgrades

WGS has been the subject of a number of analyst reports. The Goldman Sachs Group lifted their target price on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. TD Cowen upped their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Wells Fargo & Company raised their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Finally, Craig Hallum upped their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.